Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 5/20 | 0.35 |
| ▸ | HTR1D | P28221 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609999 | 0.85 | ALDH1A1 (0.36) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL25535466 | 0.74 | ALDH1A1 (0.35) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL255506 | 0.74 | HTR5A (0.34) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL12726075 | 0.73 | ESR1 (0.37) | — | |
| SCHEMBL26461102 | 0.72 | KDM4E (0.30) | ALDH1A1ALOX15MAPTCYP1A2 | |
| SCHEMBL14063515 | 0.72 | ALDH1A1 (0.42) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL26461108 | 0.70 | — | — | |
| SCHEMBL5872563 | 0.69 | HTR2A (0.36) | ALDH1A1HPGDALOX15HSD17B10HTR1D | |
| SCHEMBL17177458 | 0.69 | — | — | |
| SCHEMBL31169439 | 0.69 | KIF11 (0.44) | ALDH1A1HPGDKIF11HTR1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230270753-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11702408-B2 | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | ALDH1A1 2117/4885HPGD 2140/4885ALOX15 1696/4885 |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | ALDH1A1 4349/4885HPGD 2697/4885ALOX15 4675/4885 |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | ALDH1A1 4269/4885HPGD 713/4885ALOX15 3393/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | ALDH1A1 2816/4885HPGD 1683/4885ALOX15 4584/4885 |
| US-20230270753-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA2 | ALDH1A1 1044/4885HPGD 3483/4885ALOX15 1135/4885 |
| US-11702408-B2 | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | ALDH1A1 807/4885HPGD 377/4885ALOX15 880/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | ALDH1A1 4497/4885HPGD 4001/4885ALOX15 1776/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | ALDH1A1 894/4885HPGD 507/4885ALOX15 1271/4885 |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | ALDH1A1 2117/4885HPGD 2140/4885ALOX15 1696/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | ALDH1A1 4739/4885HPGD 3653/4885ALOX15 3271/4885 |
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | ALDH1A1 929/4885HPGD 431/4885ALOX15 914/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | ALDH1A1 1347/4885HPGD 2928/4885ALOX15 200/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | ALDH1A1 648/4885HPGD 1777/4885ALOX15 2143/4885 |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, HBG1 | ALDH1A1 1079/4885HPGD 209/4885ALOX15 1491/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALDH1A1 312/4885HPGD 1749/4885ALOX15 214/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | ALDH1A1 2117/4885HPGD 2140/4885ALOX15 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.